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Abstract 
Since the results of the Women's Health Initiative (WHI) study were published in 
2002, millions of women and their healthcare practitioners have had to re-examine 
decisions about the use of hormone replacement therapy. This level one descriptive study 
explored the characteristics of menopausal women who could not tolerate estrogen 
withdrawal and continued taking hormone replacement therapy despite fmdings of risk 
published in the Women's Health Initiative. The sample included the medical records of 
1,195 patients in a single-physician OB-GYN practice in northeast Florida. All records of 
women with a birth date in 1954 or prior and a visit to the practice for gynecological care 
between July 2002 and March 1, 2004 were reviewed to collect data about demographics, 
past medical history, and hormone replacement therapy (HRT) use. 
A significant portion of women (77.2%) had discontinued HRT. Of the women 
remaining on HRT, 54.7% changed either the dose or type of hormones taken. Only 
59.5% of these women remained on the same estrogen dose both before and after the 
WHI results were published in 2002. Interestingly, there were 29 women (4%) who 
initiated HR T use after July 2002. The women who remained on HR T after WHI were 
more likely to be younger, Caucasian (72. 7% ), non-smokers (82.3% ), and taking 
medication for other conditions (68.5%). The older the woman, the less likely she was to 
have continued HRT. Younger women were more likely to have changed HRT drug 
and/or dose post-WHI. 
CHAPTER 1 
INTRODUCTION 
What are the characteristics of menopausal women who continue hormone 
replacement therapy (HR T) despite the warnings published from the Women's Health 
Initiative Study (WHI) and why is it important? In 2003, an estimated 30 million women 
in the United States were either going through the process of menopause or had already 
completed it. An anticipated 6 million more women will reach menopause over the next 
decade, doubling the number of women over age 50 by the year 2020 (Theroux & Taylor, 
2003). Before the results ofWHI were published in July 2002, it is estimated that 6 
million women were taking hormone replacement therapy. By May 2003, only an 
estimated 2.7 million were taking HRT. Within a year, millions of women stopped using 
HRT and many more did not start due to the findings published by WHI (Goldstein, 
2004; Hersh, Stefanick, & Stafford, 2004). The women who continued HRT despite the 
risks did so primarily to reduce menopausal symptoms and maintain quality of life (Hays, 
2003; Rymer, Wilson, & Ballard, 2003; Woodward, 2005). 
Advanced registered nurse practitioners (ARNP) and other health care providers 
offering care to women must have an understanding about the perimenopausal and 
menopausal periods, and knowledge about the health risks, health promotion, and 
counseling needs of this group of women. The average age of menopause today is 51.4 
years and a healthy 50 year-old has a life expectancy of91 years (Goldstein, 2004). 
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Three-fourths of women report vasomotor symptoms at menopause and one-fourth of all 
menopausal women seek treatment for menopausal symptoms (Poindexter & Wysocki, 
2004). Since modem women live as many as one-third of their years in the post-
menopausal state (Poindexter & Wysocki, 2004), health care practitioners are obligated 
to identify patients at risk, and promote health, effective decision-making, and quality of 
life in this large segment of the population. 
Purpose 
The purpose of this study was to describe the characteristics of menopausal 
women who either remain on HRT or restart HRT after a trial discontinuation subsequent 
to the WHI results published in July 2002. If the population of women who cannot 
tolerate withdrawal from estrogen can be identified, a population at increased risk for 
adverse health events such as myocardial infarction, stroke, venous thromboembolism, 
dementia, and breast cancer could be recognized and health care interventions initiated to 
prevent these complications (Breslau, 2003; Grady, 2003; Hays, 2003). Non-hormonal 
therapy and lifestyle change methods of dealing with the symptoms of menopause could 
be researched and prescribed, reducing risk and improving the quality of life for many 
women. 
The research question examined in this study is: What are the characteristics of 
women who chose to remain on, begin or restart hormone replacement therapy after the 
results of the WHI were made public? 
Definitions 
Several terms are defined theoretically and operationally for the purposes of this 
study. Menopause is theoretically defmed as absence of menstrual periods for one year 
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following the loss of ovarian function (National Cancer Institute, 2005). Systemic 
declines in estrogen production from the ovaries during menopause have a huge impact 
on estrogen receptive tissues. The thermoregulatory center in the brain becomes unstable 
causing hot flashes. Sleep disturbances, palpitations, vaginal dryness, and thinning of the 
vaginal mucosa are other changes associated with the climacteric (Liu, 2004 ). 
Operationally, a woman is considered menopausal if she is so identified by the physician 
in the medical record. 
Hormone replacement therapy is defined theoretically and operationally as any 
formulation of estrogen with or without progestin taken by any delivery route including 
oral, transdermal, injectable, vaginal rings, vaginal tablets, or vaginal cream (Liu, 2004 ). 
Theoretical Framework 
The theoretical framework for this research was the midrange theory of reasoned 
action and planned behavior by leek Ajzen and Martin Fishbein. Originally written in 
1967 as the theory of reasoned action, it was updated in 1988 to counter criticisms that it 
did not address social influences (Ajzen, 1991; Fishbein & Ajzen, 1975). The theory was 
developed to, "provide a useful framework for predicting and understanding social 
behavior in general and health behavior in particular" (Werner, 2004, p.126). According 
to this theory, individuals are rational and able to process information and can use 
information to make reasonable behavioral decisions. The key components for reasoned 
action in women making decisions on whether or not to use HR T are identified by Azjen 
and Fishbein as knowledge, behavioral beliefs, normative beliefs, and control beliefs. 
Knowledge is the primary factor in this model, followed by attitudes towards the decision 
to be made, subjective norms of the community, and beliefs regarding ability to influence 
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outcome (Ajzen, 1991; Fishbein & Ajzen). Information concerning the risks, benefits, 
and alternatives to HRT are vital knowledge for women making treatment decisions. 
Cultural attitudes and norms towards menopause and feelings of self determination affect 
women's ability to make informed decisions on treatment of menopausal symptoms. 
Fishbein and Ajzen assert that intention to perform a behavior is a major 
determinant of planned behavior and three factors determine intention: attitude, 
subjective norm, and perceived behavioral control. Attitude is defined as the degree of 
positive or negative feelings the individual has about performing a behavior. Subjective 
norm is defined as the individual's perceived ideas about how significant others and 
society feel about a specific behavior. Perceived behavioral control refers to the 
individual's beliefs about the extent to which they have the resources or opportunity to 
perform the specific behavior (Werner, 2004). 
The theory of reasoned action and planned behavior is applicable to this study as 
millions of women struggle to decide if hormone replacement therapy for reduction of 
menopausal symptoms is worth the risks publicized by the WHI study. Self-efficacy, 
knowledge, and support are vital to women as they make informed healthcare choices 
(Wilhelm, 2002). 
CHAPTER2 
REVIEW OF LITERATURE 
This chapter provides an overview of the state of knowledge from current 
literature concerning menopause, hormone replacement therapy, the results of the WHI 
study, and its impact on women's healthcare. Alternatives to hormone replacement 
therapy and areas for further research are also presented. 
Menopause 
Menopause is defmed as absence of menstruation for one year following the loss 
of ovarian function (National Cancer Institute, 2005). Menopause is a normal transition 
from the reproductive stage to the non-reproductive stage of a woman's life. During 
menopause, there is a loss of ovarian follicular activity resulting in increases of follicle 
stimulating hormone and lutenizing hormone, decreases of estrogen and progesterone, 
and a cessation of menstruation (George, 2002). As women age, the decreased levels of 
estrogen present during perimenopause and menopause can cause a variety of symptoms 
and potentially serious health problems. 
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Qualitative studies of menopause reveal that no two women experience 
menopause in the same way (George, 2002; Wilhelm, 2003). Subjective symptoms of 
menopause include vaginal dryness, dysparunia, pain on urination, and urinary frequency 
and incontinence (Bertero, 2003). 
Vasomotor symptoms, commonly called "hot flashes," are one of the hallmark 
symptoms of menopause. While the cause of vasomotor instability is uncertain, the 
literature reports that up to seventy-five percent of women over age 45 experience hot 
flashes (Bertero, 2003; Guttuso, Kurian, McDermott, & Kieburtz, 2003). Eighty-five 
percent of women who experience hot flashes are symptomatic for more than one year 
and 25% to 50% report symptoms for up to five years (Fitzpatrick & Santen, 2002). 
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Hot flashes and sweating that occur at night are commonly labeled night sweats 
and are physiologically the same phenomenon (North American Menopause Society, 
2004 ). Night sweats are often disruptive to sleep and frequent awakening has been linked 
to mild depression, changes in attention span and memory, irritability, fatigue, and 
decreased quality of life (Fitzpatrick & San ten, 2002; Liu, 2004 ). 
Other reported symptoms of menopause believed to be caused by decreased 
hormone levels include increased perspiration, chills, palpitations, forgetfulness, 
insomnia, difficulty concentrating, mood alterations, early awakening, and breast 
soreness (Barnabei, 2002; Dennerstein, 2000; Dormire, 2003; George, 2002). 
Accelerated bone loss leading to osteopenia and osteoporosis is a potentially 
serious complication of menopause. The link between estrogen depletion and bone loss 
has been recognized for over sixty years (Fitzpatrick, 2004). Osteopenia is a thinning of 
bone tissue which unchecked progresses to osteoporosis or a substantial loss of bone 
mass. The fractures that occur with minimal trauma in osteoporotic women have a 
significant effect on mortality and morbidity (Love). Peak bone mass is usually achieved 
at age 20 and maintained until age 35. Dual energy x-ray absorptiometry (DEXA) scans 
are a diagnostic tool used to measure bone density as compared to peak bone mass. 
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Scores are reported as T scores, which represent standard deviations from the norm. A T 
score of -2.5 or greater is diagnostic for osteoporosis (Love, 2004 ). One in four 
postmenopausal women is diagnosed with osteoporosis and an additional one in three has 
osteopenia, making it of great concern to healthcare professionals. 
Menopause is a, "normal transition that occurs in all women" (Pearson, 2002, 
p.1 ). While some women become menopausal with little difficulty, other women have 
symptoms that disrupt their lives. Discomfort from hot flashes is the most common 
reason women seek HR T and these vasomotor symptoms have been shown to have a 
significant negative impact on quality of life (Barton, Loprinzi, & Waner-Roedler, 2001). 
Treatment of Menopausal Symptoms Using Hormone Replacement Therapy 
In 2000, Premarin, a conjugated equine estrogen hormone replacement therapy, 
was the second most prescribed drug in the United States (Rymer, Wilson, & Ballard, 
2003). In 2002, 6 of the top 100 selling prescriptions were products containing ethinyl 
estradiol or conjugated equine estrogens (Ruggiero & Likis, 2002). Prior to the published 
results of the WHI study in July 2002, HRT was the routinely prescribed standard of care 
for menopausal women. A survey of postmenopausal women aged 50-75 conducted in 
1995 found that approximately 38% of survey responders reported HRT use (Nelson, 
2002/2005) 
Hormone replacement therapy includes any formulation of an estrogen 
compound with or without progestin. Estrogen is either derived from the urine of 
pregnant mares (Premarin), or synthetically derived from plant sources (Cenestin) 
(National Institutes of Health [NIH], 2003). Estrogen products currently available in the 
United States include oral synthetic (Cenestin), oral equine (Premarin), oral micronized 
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estradiol (Estrace, Gynodial), oral esterfied (Menest), oral estropipate (Ogen, Orth-Est), 
transdennal (Estraderm, Vivelle, Climara), transdennal estrogel gel (EstroGel), injectable 
estradiol valerate in oil (Delestrogen), injectable estradiol cypionate in oil (Depo-
Estradiol), vaginal tablets (Vagifem), vaginal creams (Estrace, Premarin, Ogen) and 
vaginal rings (Estring, Femring) (Liu, 2004). Unopposed estrogen use in women with 
intact uteri has been shown to increase the risk of endometrial hyperplasia and 
endometrial cancer (U.S. Preventative Services Task Force, 2002). Combined estrogen-
progesterone therapy reduces the development of endometrial hyperplasia, and cyclical 
use of combined therapy reduces the risk of endometrial cancer to a rate similar to that of 
women not using hormone therapy (Humphries & Gill, 2003). 
Purported benefits of HRT included the reduction of vasomotor symptoms, 
cardiovascular system protection, prevention of vaginal and urinary tract atrophy, 
maintenance of bone density, and protection against memory loss, irritability, and 
depression (Rousseau, 2001 ). Clinical studies have shown that estrogen is effective in 
preventing bone loss associated with menopause (Fitzpatrick, 2004; Humphries & Gill, 
2003; Women's Health, 2004) however, Raloxifene (Evista), bisphosphonates such as 
alendronate (F osamax ), and parathonnone are alternatives to estrogen for treatment of 
bone loss which are effective and have low risk (Love, 2004 ). 
The Heart and Estrogen/Progestin Replacement Study 1 The first large 
randomized placebo-controlled study to examine estrogen use and secondary prevention 
of coronary artery disease was The Heart and Estrogen/Progestin Replacement Study 
(HERS-I), funded by Wyeth-Ayerst Laboratories and published in 1998 (NIH, 1998). 
HERS-I considered 2, 763 postmenopausal women with an average age of 67. 
Participants were randomly assigned to an estrogen/progestin combination or a placebo 
and treated for approximately 4 years (Furberg, 2002). 
Contradicting years of observational studies, HERS-I demonstrated no cardio-
protective benefits from HRT. Women in the treatment arm with heart disease found 
estrogen and progestin use did not prevent further heart attacks or death from coronary 
heart disease despite the positive effects of treatment on lipoproteins (NIH, 1998). The 
study was criticized as too short, the conclusions generally were unheeded, and the 
results did not change HRT prescribing habits. 
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The Heart and Estrogen/Progestin Replacement Study /1 To counter criticisms of 
the HERS-I study, open label observational follow-up of93% of the surviving women 
was carried out with consent for an additional2.7 years. HRT was prescribed to study 
participants at the personal physician's discretion. In the treatment group, patient usage 
ofHRT declined from 81% in the first year to 45% in the sixth year. In the placebo 
group, hormone usage increased from 0% in the first year to 8% in the sixth year. The 
Heart and Estrogen/Progestin Replacement Study II (HERS-II) analyzed data from the 
total6.8 years and again demonstrated no cardiac benefits from HRT (Hulley et al., 
2002), foreshadowing the fmdings of the WHI which were published within days of 
HERS-II. 
The Women's Health Initiative Study. The Women's Health Initiative, sponsored 
by the NIH, was an ambitious, multicenter placebo-controlled study of the effects of HR T 
on 16,608 healthy postmenopausal women aged 50-79 (Beattie, 2003). There were two 
arms of the study. The first included women with an intact uterus who received either 
combination estrogen-progesterone therapy or a placebo. The second arm examined 
unopposed estrogens effects on healthy women with prior hysterectomies (Liu, 2004). 
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WHI was established in 1991 to examine, "the most common causes of death, 
disability, and impaired quality of life in postmenopausal women" (Brucker & Youngkin, 
2002, p. 411 ). The goal was prevention of the major causes of morbidity and mortality in 
women such as heart disease, cancers of the breast and colon, and osteoporosis. 
Volunteers had varied backgrounds and demographics. The double blind study was 
designed to assign women randomly to an estrogen/progestin group and a placebo group. 
Participants were assessed every 6 months and had yearly mammogram and breast exams 
(National Institutes of Health [NIH], 2002). On July 9, 2002, the Data and Safety 
Monitoring Board of the Women's Health Initiative unexpectedly ended the combined 
hormone therapy arm of the WHI study three years early, citing increased risks for breast 
cancer, pulmonary embolisms, strokes, cardiac events, and dementia, with only a slight 
benefit of decreased fractures and colorectal cancers (Hormone Replacement, 2002). Use 
ofHRT plummeted in the wake of HERS-II and the WHI results. The NIH further 
shocked health care providers when the second arm of WHI, the trial of conjugated 
equine estrogen (Premarin) alone in women with hysterectomies, was terminated on 
March 2, 2004, one year prior to its planned completion due to an increased risk of stroke 
in participants (NIH, 2004 ). 
The WHI study is limited by the timing of initiation of estrogen and the use of 
only one oral preparation ofHRT (0.625mg/d conjugated equine estrogen either alone or 
in combination with 2.5mg/d medroxyprogesterone acetate or Prempro ). It has however, 
had a radical impact on recommendations by health care providers to postmenopausal 
women concerning HRT. 
Recommendations for Hormone Replacement Therapy since WHI 
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"The WHI is considered the most statistically valid study of HR T use in healthy 
postmenopausal women" (Voelker, 2002, p.2395) however there is some controversy 
concerning the implications for the care of menopausal women. There is also controversy 
regarding the methodology, since the average age of study participants was 63 (ACOG, 
2004), and 74.4% of these women had never used estrogen and had been estrogen 
depleted for an average of 10 years (Chlebowski, n. d.). The American College of 
Obstetrics and Gynecology (ACOG) assembled an expert panel in 2002, which issued 
guidelines in 2004 for the use of HRT in the wake of the WHI results (ACOG Task 
Force, 2004). 
ACOG stressed that each woman individually with her health care provider must 
evaluate use of hormone replacement therapy for risks and benefits. The second 
guideline stated that HRT be used for management of menopausal symptoms only and 
not as a preventative for chronic disease. The recommendations continued with a 
statement that HR T use should be evaluated periodically and at least annually, the lowest 
dose for the least amount of time should be used, and alternative therapies considered. 
Current users of HR T are advised to taper doses toward discontinuation of HR T (Hersh & 
Stafford, 2004). Women desiring long term hormone replacement therapy for general 
well-being must be counseled about the risks as WHI data concluded after four years of 
continuous HRT, diagnosis rates of invasive breast cancer significantly increased 
(ACOG, 2002). The North American Menopause Society recommendations echo ACOG 
guidelines (Utian:J 2004) as do the guidelines from the National Association of Nurse 
Practitioners in Women's Health (Wysocki, Alexander:J Schnare, Moore, & Freeman, 
2003). 
Alternative Therapies to HRT for Relief of Perimenopausal and Menopausal Symptoms 
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As clinicians inform postmenopausal women about the risks and benefits ofHRT, 
a discussion of alternative treatments for symptoms and chronic disease prevention is 
necessary. "The use of alternative therapies for menopausal symptoms is common, and 
women who use them generally find them to be beneficial" (Newto~ 2002, p. 18). 
Alternative therapies must be matched to symptoms and treatment goals and include 
lifestyle changes, alternative health care, herbal and nutritional supplements, and other 
prescription medications. 
Lifestyle changes. Lifestyle changes are suggested as the first alternative to HRT 
by the North American Menopause Society (Utian, 2004). Exercise and weight loss are 
advocated for perimenopausal women since fit women experience up to 50% less hot 
flashes than do sedentary women. Furthermore, a high body mass index is associated 
with more severe and more frequent vasomotor symptoms. Smoking and stress are also 
correlated with increased vasomotor symptoms (Kim, 2004 ). Relaxation techniques and 
deep breathing are effective methods to help control menopausal symptoms. Lower air 
temperature, use of fans, avoidance of hot beverages and foods, and layered clothing are 
other suggestions {Kim, 2004 ). Low fat diet, blood pressure control, and exercise are 
suggested for prevention of heart disease (Grimes & Lobo, 2002). Increased dietary 
intake of vitamin D and calcium in addition to weight bearing exercises are 
recommended for prevention of osteoporosis (Morley, 2004 ). 
Alternative health care. Acupuncture has been used for relief of menopausal 
symptoms by 10% of women using alternative therapies. Visits to homeopathic or 
naturopathic physicians, chiropractors, massage therapists, and herbalists are also 
reported as somewhat to very helpful by women surveyed (Newton, 2002). 
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Herbal and nutritional supplements. Herbal and nutritional supplements are 
increasingly popular; however there are no randomized controlled studies that indicate 
efficacy in these products (Kim, 2004). Vitamin E, black cohash, red clover, and dong 
quai are the most widely used herbal and nutritional supplements for menopausal 
symptoms. Clinical trials have shown either no effectiveness or conflicting results, and 
the correct dosage and duration of treatment are in dispute, but as there is little potential 
for harm, these products may remain an option for women (ACOG, 2004; Hackley & 
Rousseau, 2004; Newton, 2002). 
Phytoestrogens. Phytoestrogens are plant-derived non-steroidal compounds that 
that either have estrogenic activity or are metabolized in substances with estrogenic 
activity. Isoflavinoids, lignans, and coumestans comprise the three main groups of 
phytoestrogens (Krebs, Ensrud, MacDonald, & Wilt, 2004). While phytoestrogens are 
present in over 300 varieties of plants, legumes and particularly soybeans are rich in 
phytoestrogens. There is no evidence dietary soy intake reduces menopausal symptoms 
of hot flashes and night sweats and placebo-controlled trials on the clinical effects of 
phytoestrogens have been similar to placebo (Speroff, 2005). 
Prescription medications. Other prescription medications for menopausal 
symptoms and chronic disease prevention are available. Progestin only regimes such as 
depo-medroxyprgesterone acetate, megestrol acetate, and topical progesterone creams 
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have reduced the frequency and severity of hot flashes 80-90% in studies (Hackley & 
Rousseau, 2004). Clonidine has been shown minimally more effective than placebo 
however adverse effects including insomnia are problematic (Hackley & Rousseau, 
2004). Selective serotonin reuptake inhibitors (Effexor, Prozac, and Paxil) have proven 
effective at reduction of vasomotor symptoms in short term randomized trials and may be 
of interest in women unable or unwilling to take HRT for disruptive menopausal 
symptoms (ACOG, 2004; Evans et al., 2005; Hackley & Rousseau, 2004). Vaginal and 
genito-urinary tract symptoms may be relieved with use of topical estrogen creams, 
vaginal rings, or tablets. The use of lubricants may alleviate dysparunia. Urinary 
incontinence, urgency, and frequency may be relieved with tolterodine (Detrol), bladder 
training, and vaginal estrogen preparations (Hackley & Rousseau, 2004 ). 
Osteopenia and osteoporosis can be treated with alendronate, raloxifene, and 
parathyroid hormone. All of theses prescription medications have been shown to increase 
bone density and reduce fractuies in postmenopausal women (Love, 2004. ). 
Gabapentin, approved in 1994 for seizure therapy, is currently being studied for 
use in reduction of vasomotor symptoms in postmenopausal women. A randomized, 
double blind, placebo-controlled study of 59 postmenopausal women demonstrated a 
54% decrease in hot flashes with low dose therapy over placebo. The authors propose 
further study which is merited (Guttuso, Kurian, McDermott, & Kieburtz, 2003). 
Tibolone is a synthetic steroid promoted by the manufacturer, Organon, as having 
"tissue-specific" hormonal effects thereby increasing safety over estrogen-based drugs. 
Prescribed for relief of hot flashes, to protect from bone loss, and to improve vaginal 
tissue, tibolone is unavailable in the United States. While tibolone is used in 70 countries 
other than the U.S., The Lancet (August 9, 2003) reported United Kingdom's Million 
Women Study demonstrated an increased risk of breast cancer for women taking 
hormone therapies including tibolone (Robb-Nicholson, 2004). 
Women's Responses to HERS-I, HERS-/I, and WHI 
With the publication of the results of HERS-I in 1998 followed by HERS-II and 
WHI results within days of each other in 2002, an estimated 65% of women using HR T 
abruptly discontinued it. Reports published two years later showed that 1 in 4 women 
who discontinued HR T because of WHI findings restarted hormone therapy to relieve 
menopausal symptoms (ACOG, 2004). 
Conclusions 
The results of HERS-I, HERS-II and WHI dramatically changed women's 
healthcare. No longer were women being told HRTwas the panacea for aging. Long 
held ideas about the benefits of estrogen were proved false and millions of women 
abruptly discontinued its use. ln the wake of WHI, some women refused to discontinue 
HRT despite the increased risk for significant health problems. Research related to the 
characteristics of women unwilling or unable to stop HR T may assist in identifying a 
patient group at risk for the complications of HRT and lead to prevention of these 
problems. 
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CHAPTER3 
METHODOLOGY 
16 
The purpose of this research was to describe the characteristics of postmenopausal 
women who chose to remain on, begin, or restart hormone replacement therapy after the 
results of the WHI were made public in July 2002. A retrospective chart review of 
medical records in a single-physician OB-GYN practice in northeast Florida provided the 
data for this level one descriptive study. 
Sample 
A total non-probability convenience sample of every medical record that met the 
inclusion criteria was examined. Inclusion criteria for this study were the medical 
records of patients with a birth ·date in 1954 or earlier who were scheduled for 
gynecological care subsequent to July 2002 (the date of the cessation of the first arm of 
the WHI). A computer search on March 1, 2004 revealed approximately 1800 medical 
records that met the inclusion criteria. 
A total of I, 783 charts were reviewed. Of these, 301 were noted as "no show'' for 
the scheduled office visit, 19 had significant missing data, and 268 were seen for a non-
gynecological appointment. The total number of charts for which data were analyzed, 
therefore was 1,195. 
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Setting 
The population in the northeast Florida area where the practice is located is 
90.0% white, 7.7% black or African-American, 1.5% Hispanic, and 0.5% Asian (U.S. 
Census Bureau, 2006). The median family household income is $49,845. Forty one 
percent of the population ofNassau County is age 45 and older (Nassau County 
Economic Development Board, 2004 ). An investigation of 100 randomly chosen medical 
records at the practice site on April 11, 2004, showed a close match with the 
demographic data of the county. 
Data Collection Procedure 
Every medical record that met the inclusion criteria was reviewed by the primary 
investigator. Data collection for this study took place from June 2004 to January 2005. 
No identifying data were collected. Patients were considered menopausal with a 
diagnosis of menopause on the chart. 
Instrument 
Data concerning the characteristics of menopausal women were collected using a 
data sheet developed for the research (See Appendix A). Demographic data included 
age, gravida and para, natural or surgical menopausal status, age at menopause, race, and 
marital status. Medical history included current weight, recent weight loss or gain, blood 
pressure, smoking status, other medical diagnoses, current medications, gynecological 
surgeries, mammogram BiRADS classification, and DEXA scan results. Current and 
previous hormone therapy, menopausal symptoms reported, and treatment for 
menopausal symptoms which were documented in the medical record were examined. 
18 
Protection of Human Subjects 
This research was reviewed by the Institutional Review Board at the University of 
North Florida and granted approval as Exempt/Category 4 (See Appendix B). The chart 
review recorded no identifYing data, and the data sheets were shredded once the 
information was tabulated, entered into a spreadsheet, and verification of accuracy was 
accomplished. 
CHAPTER4 
RESULTS 
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A descriptive analysis of the data was conducted. This chapter summarizes the 
data regarding the characteristics of menopausal women who either continued, began, or 
restarted hormone replacement therapy during the two years after the publication of 
results from the WHI. 
Demographic Data 
A total of 1,195 charts was reviewed. The mean age of the patients was 61.36 at 
the time of data collection. Most of the women were Caucasian (82. 7% ), married 
(76.5%), and multiparous (81.3%) (see Table 4.1). The vast majority (92.2%) were 
menopausal (see Table 4.2). Menopause was surgical in 29.3% of women, with total 
abdominal hysterectomy and bilateral salpingo-oopherectomy performed 60.4% of the 
time. The majority of surgeries (60.3%) were performed for menometrorrhagia. 
Sixty four percent of women whose records were reviewed reported other medical 
diagnoses and 71.1% reported taking medications other than HRT. The top four medical 
diagnoses that included pharmacologic management were hypertension (23.6%), thyroid 
dysfunction (14.5%), osteoporosis (11.7%), and depression (11.7%). Smoking at some 
time in the past was reported by 19.8% of women and current smoking was reported by 
17.7%. Caffeine intake was reported by 71.4% of women. Bone density results were 
tabulated from DEXA scans with approximately one-third of women with 
Table 4.1 
Demograf!..hic Characteristics of Samf!..le 
Characteristic n % 
Race (n = 1,169) 
Caucasian 967 82.7% 
African American 162 13.9% 
Other 40 3.4% 
Marital Status (n = 1,164) 
Married 890 76.5% 
Single 52 4.5% 
Divorced/Separated 103 8.8% 
Widowed 119 10.2% 
Parity (n = 1,182) 
Nullipara 99 8.4 
Primipara 122 10.3 
Multipara 804 68 
Grand MultiEara 157 13.3 
Table 4.2 
Initiating Events [or Menopause (n= 1195) 
Menopausal Status n 
Non-menopausal 93 
Natural Menopause 649 
Surgical Menopause 453 
Menometrorrhagia (n = 273) 
Ovarian Mass (n = 28) 
Fibroid Uterus (n = 50) 
Diagnosis Not Listed (n = 101) 
Cancer (n = 1) 
% 
7.8% 
54.3% 
37.9% 
osteoporosis, one-third with osteopenia, and one-third with normal bone density (see 
Table 4.3) 
The average time on HRT for the sample as a whole was 8.3 years (range= 0 to 
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46). Seven hundred-thirty of the 1,195 women on whom charts were reviewed ( 61.1%) 
had been on hormone replacement therapy prior to the release of the WHI results in July 
2002. Four hundred-forty-three of the women on whom charts were reviewed (37.1 %) 
were on hormone replacement therapy at the time of data collection (See Figure 4.1 ). 
Table 4.3 
Bone Density DEXA Scan Results (n = 129) 
Osteoporosis (T score -2.5 or less) 
Osteopenia (T score -1.0 to -2.4) 
Normal bone density (T score > -1.0) 
n 
46 
44 
39 
% 
35.7% 
34.1% 
30.2% 
Of the women for whom both pre and post WHI data on HRT use were available 
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(n= 724), 254 discontinued HRT after July 2002. Of the 75 women remaining on HRT, 
41 changed either the dose or type of hormones taken (see Figure 4.2). Only 59.5% of 
women taking HRT after July 2002 remained on the same estrogen dose both before and 
after WHI results were published (See Figure 4.3). Interestingly, there were 29 women 
(4%) who initiated HRT use after July 2002. 
0395 
Figure 4.1 Overall Effect ofWHI on HRT Use 
Percent of 
patients 
COn HRT 
before 
WHI 
con HRT 
afterWHI 
Figure 4.2 Effect of WHI Results on HRT Use 
0254 
• HRT Unchanged 
EJ Changed HRT Dose or 
Drug 
0 Stopped HRT 
o Never on HRT 
,. 
Figure 4.3 Overall Effect ofWHI on Estrogen Dose 
. 
Percent of 
patients 
I'J Pre-WHI 
estrogen 
dose 
<0.625mg 
DPost-WHI 
estrogen 
dose 
<0.625mg 
The women who remained on HRT after WHI were more likely to be younger, 
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Caucasian, and married (See table 4.4), non-smokers (82.3%), and taking medications for 
other conditions (68.5%). The older the woman, the less likely she was to have continued 
HRT. Younger women were more likely to have changed HRT drug and/or dose post-
WHI. 
For women with an HRT history, 43.6% reported no symptoms offHRT, 29.1% 
reported symptoms when HRT was discontinued, and 27.2% were never offHRT. Of 
those who reported menopausal symptoms with the discontinuation ofHRT, 36.5% took 
no medication to relieve symptoms while 31.1% reported restarting HRT. Additional 
treatments used for menopausal symptoms among those who discontinued HRT included 
sleeping pills for insomnia (9.8%), Vagifem (7.6%) and vaginal lubricants (4.8%) for 
vaginal dryness and dyspareunia, herbal supplements for general relief of symptoms, 
D & C for menometrorrhagia (1.9% ), selective serotonin reuptake inhibitors (SSRis) for 
depression (1.3%), and pessaries for urinary incontinence (0.6% ). 
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Table 4.4 
Comp_arison of Characteristics of Women by_ HRT Use Pre and Post WHI 
Pre WHI PostWHI Total 
NoHRT HRT NoHRT HRT Sample 
n % n % n % n % n % 
Number of Women with 431 56.7 329 43.3 708 61.5 443 38.5 1195 100 
HRTHistory 
Mean Age 62.6 62.1 62.3 60.6 61.4 
Race 
Caucasian 353 49.2 259 36.1 596 52.4 348 30.6 967 82.7 
African American 52 7.2 32 4.5 75 6.6 80 7.0 162 13.9 
Other 14 1.9 8 1.1 24 2.1 14 1.2 40 3.4 
Marital Status 
Married 312 46.6 190 28.4 521 46.0 345 30.5 890 76.5 
Single 23 3.4 2 0.3 23 2.0 28 2.5 52 4.5 
Divorced/Separated 37 5.5 21 3.1 66 5.8 35 3.1 103 8.8 
Widowed 49 7.3 36 5.4 80 7.1 35 3.1 119 10.2 
Discussion of Findings 
CHAPTERS 
DISCUSSION 
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The published fmdings of WHI radically changed healthcare for menopausal 
women, both nationally and in the study population. With significant numbers of women 
abruptly terminating HRT, menopausal symptoms again became an issue for many 
women. OfWHI participants, 63.3% report at least one moderate or severe symptom 
after discontinuing HRT. It is important to note that 40.5% of placebo group participants 
also report moderate to severe symptoms after placebo discontinuation (Petitti, 2005), 
suggesting that symptoms previously attributed to a lack of estrogen may in fact have 
other causes. This study found that younger, Caucasian, non-smoking women taking 
medications for other conditions were more likely to remain on HRT after WHI. 
Additionally, younger women in general were more likely to have changed HRT drug or 
dose post-WHI by lowering the estrogen dose to below 0.625mg. With information about 
menopause and HRT and counseling regarding the findings of WHI, one in four women 
nationally have resumed taking HRT for moderate to severe menopausal symptoms 
(ACOG, 2004). The increased numbers of women (37%) in this study who remained on 
HRT post-WHI might be attributable to this fairly homogeneous sample of predominately 
Caucasian, upper-middle-class women. 
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No published studies were found describing the characteristics of women who 
either continued HR T or resumed hormone therapy despite the substantial risks 
delineated in WHI. Currently, WHI' s applicability to all postmenopausal women is 
coming under scrutiny. Francine Grodstein of Harvard University, in an article published 
in January, 2006, reports fmdings contradictory to WHI results. The results of her study 
found women beginning HRT near the start of menopause had a significantly (30%) 
lower risk of coronary heart disease (CHD) compared to menopausal women who had 
never taken HRT. In a subgroup of women similar demographically to WHI participants, 
no relationship was found between HRT use and CHD (Grodstein, Manson, & Stampfer, 
2006). 
Hormone therapy remains controversial and many questions remain unanswered. 
One thing experts agree on is HRT should be used for treating hot flashes and vaginal 
dryness at the lowest effective dose for the shortest amount time (ACOG, 2004; 
Woodward, 2005). 
Limitations 
Limitations of this study included missing pieces of data, the potential for error 
with patient self-reporting and staff assumptions in initial recording of data in the chart, 
and the utilization of a single facility for data collection. 
The original number of charts reviewed was 1, 783 with 85 potential pieces of 
information retrieved from each chart. This voluminous amount of data was recorded by 
one researcher on a data collection sheet and then entered by the researcher and two 
assistants into an Excel spreadsheet allowing for the introduction of typographical errors. 
Missing data was frequently encountered and only 724 charts contained HRT data both 
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pre and post-WHI. Limiting the sample size by eliminating charts without pre and post-
WHI hormone use data would have made for more manageable data collection, 
recording, and analysis. 
The use of a retrospective chart review did not allow for the consistent initial 
recording of the data. Patients self reported much of the demographic data; however race 
was recorded by the medical assistant, nurse, or physician doing the initial assessment 
and may have differed from what the patient would have reported. Education levels were 
not recorded which may have affected the results. Patient interviews conducted from a 
script by one interviewer would have provided consistent and more complete data than 
the retrospective chart review undertaken for this study. 
This study is further limited by the fact that all patients visited a single physician 
in a rural practice setting. Replication of these fmdings from several practices in urban, 
suburban and other rural settings would validate the findings. 
Implications for Further Study 
Further research is desperately needed in the area ofHRT for post-menopausal 
women. Limitations in the sample used in WHI must be addressed so women and their 
health care providers can make informed choices about treatments for menopausal 
symptoms and chronic diseases. Studies of women initiating HRT at the time of 
menopause are required as this is the point when most women initiate hormone therapy. 
Reports of resumption of vasomotor symptoms upon discontinuation of HRT ("Study 
Shows HT May," September 2005) add additional problems to the issue. Further 
research into alternative treatments for vasomotor symptoms would be useful for women 
unwilling or unable to take HR T. 
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Conclusions 
The premature end of the WHI study and findings of substantial risk with HR T 
changed long-standing practices with regard to the treatment of post-menopausal women. 
The literature reports that almost two years after the publication of the results of the WHI 
study, many women remain confused about the risks and benefits of hormone 
replacement therapy. Seventy-five percent of respondents to a survey published in the 
Journal of the American Medical Women's Association reported that they needed 
additional information about hormone replacement therapy and consequences (Breslau, 
2003 ). Health care providers need to be current on the research and recommendations 
regarding HRT and the treatment of menopausal symptoms and counsel their 
postmenopausal patients appropriately. As Margaret Freda, editor of the American 
Journal of Maternal Nursing wrote, "If we believe in evidence-based practice, now is the 
time for us to read studies and practice accordingly, teaching our patients and helping 
them understand this issue. Our practice, as well as our collective mind-set about 
menopause needs to change." (Freda, 2003. p. 259). 
The theory of reasoned action and planned behavior would assert that women 
must receive accurate information concerning the risks, benefits, and alternatives to HR T 
if they are to be empowered to make informed decisions about the treatment of their 
menopausal symptoms (Azjen and Fishbein, 1975). The results of the current study 
underscore that treatment decisions by both health care providers and the women for 
whom they care have been heavily influenced by the results of WHI. 
As the numbers of postmenopausal women increase, the need for safe and 
effective therapies for symptoms and chronic diseases associated with menopause 
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becomes more pressing. Research on HRT other than conjugated equine estrogen and 
non-oral delivery systems needs to be conducted to see if the results mimic those of the 
WHI study. Studies on alternative treatment need to be undertaken to determine 
effectiveness, clarify dosage regimes, and define benefits and risks. Timing of HR T in 
relation to menopause needs to be examined. Women who cannot tolerate estrogen 
withdrawal need to be identified, counseled about risks and benefits of HR T, and offered 
alternatives to treat symptoms and preserve quality of life. 
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APPENDIX A 
RESEARCH TOOL: CHARACTERISTICS OF MENOPAUSAL WOMEN 
+Demographic data 
Age: __________ ( doh 1954 and earlier) G ___ P __ _ 
Menopausal? _______ if surgically menopausal, list surgery: _____ _ 
Age at menopause: _____ race: _______ marital status: ____ _ 
BP: _____ current weight: ___ recent wt loss or gain? ___ amt? __ _ 
+Hormone replacement therapy usage 
Previous methods of birth control: 
---------------------------
HRT currently? ____ _..previously? ___ type/dose: __________ _ 
Length of time on HRT: _____________________ _ 
Symptoms on discontinuation ofHRT: 
-------------------
Treatment for symptoms? _____________________ _ 
+Past medical history 
Any gyn surgeries? (list) 
-------------------------
Other diseases (hypertension, heart disease, thyroid, diabetes, cancers): ______ _ 
Current Medications: 
------------------------
Smoke currently? ____ in past? _______ caffeine use? ___ _ 
T score Birads 
---------
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